T Hedley Carr
Overview
Explore the profile of T Hedley Carr including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
584
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cani A, Dolce E, Darga E, Hu K, Liu C, Pierce J, et al.
Mol Oncol
. 2021 Dec;
16(10):1969-1985.
PMID: 34866317
Nearly all estrogen receptor (ER)-positive (POS) metastatic breast cancers become refractory to endocrine (ET) and other therapies, leading to lethal disease presumably due to evolving genomic alterations. Timely monitoring of...
2.
Carr T, Adelman C, Barnicle A, Kozarewa I, Luke S, Lai Z, et al.
Cancers (Basel)
. 2021 Nov;
13(22).
PMID: 34830984
Background: Phase III randomized trial data have confirmed the activity for olaparib in homologous recombination repair (HRR) mutated metastatic castration-resistant prostate cancer (mCRPC) post next-generation hormonal agent (NHA) progression. Preclinical...
3.
Smyth L, Batist G, Meric-Bernstam F, Kabos P, Spanggaard I, Lluch A, et al.
NPJ Breast Cancer
. 2021 Apr;
7(1):44.
PMID: 33863913
Five to ten percent of ER+ metastatic breast cancer (MBC) tumors harbor somatic PTEN mutations. Loss of function of this tumor-suppressor gene defines a highly aggressive, treatment-refractory disease for which...
4.
Kingston B, Bailleux C, Delaloge S, Schiavon G, Scott V, Lacroix-Triki M, et al.
JCO Precis Oncol
. 2020 Sep;
3.
PMID: 32923864
No abstract available.
5.
Mohan S, Foy V, Ayub M, Leong H, Schofield P, Sahoo S, et al.
J Thorac Oncol
. 2019 Oct;
15(2):216-230.
PMID: 31629061
Introduction: SCLC accounts for approximately 250,000 deaths worldwide each year. Acquisition of adequate tumor biopsy samples is challenging, and liquid biopsies present an alternative option for patient stratification and response...
6.
Rowlands V, Rutkowski A, Meuser E, Carr T, Harrington E, Barrett J
Sci Rep
. 2019 Sep;
9(1):12620.
PMID: 31477768
Liquid biopsies offer the potential to monitor cancer response and resistance to therapeutics in near real-time. However, the plasma cell free DNA (cfDNA) level can be low and the fraction...
7.
Paoletti C, Schiavon G, Dolce E, Darga E, Carr T, Geradts J, et al.
Clin Cancer Res
. 2018 Aug;
24(23):5860-5872.
PMID: 30082476
Purpose: Common resistance mechanisms to endocrine therapy (ET) in estrogen receptor (ER)-positive metastatic breast cancers include, among others, ER loss and acquired activating mutations in the ligand-binding domain of the...
8.
Ellison G, Ahdesmaki M, Luke S, Waring P, Wallace A, Wright R, et al.
Hum Mutat
. 2017 Dec;
39(3):394-405.
PMID: 29215764
Ovarian cancer patients with germline or somatic pathogenic variants benefit from treatment with poly ADP ribose polymerase (PARP) inhibitors. Tumor BRCA1/2 testing is more challenging than germline testing as the...
9.
Banerji U, Dean E, Perez-Fidalgo J, Batist G, Bedard P, You B, et al.
Clin Cancer Res
. 2017 Oct;
24(9):2050-2059.
PMID: 29066505
This phase I, open-label study (Study 1, D3610C00001; NCT01226316) was the first-in-human evaluation of oral AZD5363, a selective pan-AKT inhibitor, in patients with advanced solid malignancies. The objectives were to...
10.
Ahdesmaki M, Chapman B, Cingolani P, Hofmann O, Sidoruk A, Lai Z, et al.
PeerJ
. 2017 Apr;
5:e3166.
PMID: 28392986
Sensitivity of short read DNA-sequencing for gene fusion detection is improving, but is hampered by the significant amount of noise composed of uninteresting or false positive hits in the data....